Your browser doesn't support javascript.
loading
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
Mariottini, Alice; Lotti, Antonio; Innocenti, Chiara; Repice, Anna Maria; Nozzoli, Chiara; Boncompagni, Riccardo; Fainardi, Enrico; Saccardi, Riccardo; Massacesi, Luca.
  • Mariottini A; Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
  • Lotti A; Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy.
  • Innocenti C; Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
  • Repice AM; Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
  • Nozzoli C; Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy.
  • Boncompagni R; Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
  • Fainardi E; Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
  • Saccardi R; Neuroradiology Unit, Careggi University Hospital, Florence, Italy.
  • Massacesi L; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Eur J Neurol ; 30(10): 3362-3366, 2023 10.
Article en En | MEDLINE | ID: mdl-37483174
ABSTRACT
BACKGROUND AND

PURPOSE:

It is still debated whether the COVID-19 pandemic affected disease activity in people with autoimmune diseases, including multiple sclerosis (MS). The aim of this study, therefore, was to explore the impact of COVID-19 in people with MS (pwMS) not receiving continuative disease-modifying therapy (DMT) after previous treatment with autologous hematopoietic stem cell transplantation (AHSCT). MATERIALS AND

METHODS:

We included pwMS treated with AHSCT who were in disease remission without receiving DMTs during the pandemic and who were followed up at our centre during the study period. Data on SARS-CoV-2 infection and vaccination were recorded, with details of adverse events and clinical-radiological disease activity.

RESULTS:

A total of 36 pwMS (31 females; 86%) were included, of whom 23 (64%) had relapsing-remitting (RR-MS) and 13 had secondary progressive MS (SP-MS). Thirty-three pwMS (92%) received anti-SARS-CoV-2 mRNA vaccines. Thirteen patients (36%) developed mild to moderate COVID-19 a median (range) of 58 (4-224) months after AHSCT; seven (54%) of these patients were not yet vaccinated. Transient neurological symptoms after vaccination or infection were reported in 9% and 36% of the patients, respectively. The rate of new inflammatory events (relapses or asymptomatic magnetic resonance imaging [MRI] activity) after AHSCT increased from 0.006 (one asymptomatic new lesion/159 patient-years) before the pandemic to 0.083 (five relapses plus two cases of asymptomatic MRI activity/84 patient-years) since the pandemic start (p = 0.004).

CONCLUSIONS:

People with MS with a history of highly active disease, who are untreated or receiving moderate-efficacy DMTs might be more vulnerable to disease reactivation, possibly elicited by exogenous triggers. Careful monitoring and further investigation are warranted to ascertain whether special precautions are needed in these cases.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Esclerosis Múltiple Recurrente-Remitente / COVID-19 / Esclerosis Múltiple Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Esclerosis Múltiple Recurrente-Remitente / COVID-19 / Esclerosis Múltiple Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article